Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine dosing for postoperative recovery after modified radical mastectomy
ChiCTR2000034930Phase 4Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in breast cancer (3 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: QoR-40 (40-item quality of recovery score) and Neutrophil-to-lymphocyte ratio (NLR). Started Nov 2020; status: recruiting.
02
Drugs
esketamine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000034930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034930.